ACS Chemical Neuroscience Molecule Spotlight on Semagacestat (LY450139)

作者：Hopkins Corey R^*

来源：ACS Chemical Neuroscience, 2010, 1(8): 533-534.

DOI：10.1021/cn1000606

• Gamma-secretase
• Alzheimer's disease
• AD
• neurodegeneration
• LY450139
• semagacestat

Semagacestat (LY450139) is a novel gamma-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.

• 出版日期2010-8